Akron Children's > For Families & Patients > Research > Pediatric Clinical Studies > Open Clinical Studies
Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis
Full IRB Study Title:
A Phase 2, Randomized, Double‑blind, Controlled Study to Evaluate the Safety of VX‑152 Combination Therapy in Adults With Cystic Fibrosis Protocol: VX16-152-102
IRB Study ID: 968803-8
For complete study information, please visit clinicaltrials.gov
Study Sponsor:
Vertex Pharmaceuticals Incorporated
Lead Investigator
Gregory Omlor, MD, FAAP
Director, Lewis H Walker CF Center; Pediatric Pulmonologist; Pediatric Sleep Medicine
Lewis H. Walker, MD, Cystic Fibrosis CenterRobert T. Stone, MD, Respiratory CenterPediatric Sleep Medicine
